#biotech IPO

BlossomHill Therapeutics Falls Post-$150M IPO in Cautious Biotech Debut

BlossomHill Therapeutics' post-IPO decline highlights investor caution toward cancer drugmakers, with the $150 million debut faltering on U.S. exchanges as biotech sentiment…

Attovia Therapeutics Stock Surges 24% After $289 Million IPO

Attovia Therapeutics stock jumps 24% in trading debut after $289 million biotech IPO, reflecting strong demand for new healthcare listings.

A16z-Backed Braveheart Biotech Seeks $318.8 Million in US IPO

A16z-backed Braveheart seeks $318.8 million in a US IPO, signaling continued vigor in the venture-backed biotech market.

Eli Lilly-backed Scribe Therapeutics files for $107.2 million IPO

Scribe Therapeutics, with Eli Lilly’s backing, files for a $107.2 million IPO, highlighting gene-editing sector momentum and potential biotech IPO revival.